NZ568206A - Use of a composition for preserving organs and limbs - Google Patents
Use of a composition for preserving organs and limbsInfo
- Publication number
- NZ568206A NZ568206A NZ568206A NZ56820606A NZ568206A NZ 568206 A NZ568206 A NZ 568206A NZ 568206 A NZ568206 A NZ 568206A NZ 56820606 A NZ56820606 A NZ 56820606A NZ 568206 A NZ568206 A NZ 568206A
- Authority
- NZ
- New Zealand
- Prior art keywords
- use according
- composition
- oxygen
- ambient temperature
- semifluorinated alkane
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 61
- 210000000056 organ Anatomy 0.000 title claims abstract description 40
- -1 alkane compound Chemical class 0.000 claims abstract description 47
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000007788 liquid Substances 0.000 claims abstract description 17
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 34
- 229910052760 oxygen Inorganic materials 0.000 claims description 34
- 239000001301 oxygen Substances 0.000 claims description 34
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 17
- 229920002545 silicone oil Polymers 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 239000013543 active substance Substances 0.000 claims description 7
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 235000015097 nutrients Nutrition 0.000 claims description 5
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 4
- WRYIIOKOQSICTB-UHFFFAOYSA-N 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluorotetradecane Chemical compound CCCCCCCCC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F WRYIIOKOQSICTB-UHFFFAOYSA-N 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 229940108325 retinyl palmitate Drugs 0.000 claims description 3
- 235000019172 retinyl palmitate Nutrition 0.000 claims description 3
- 239000011769 retinyl palmitate Substances 0.000 claims description 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 2
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 claims description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 2
- 229960004308 acetylcysteine Drugs 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 235000006708 antioxidants Nutrition 0.000 claims description 2
- 239000000824 cytostatic agent Substances 0.000 claims description 2
- 230000001085 cytostatic effect Effects 0.000 claims description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 2
- 229960001680 ibuprofen Drugs 0.000 claims description 2
- 150000002632 lipids Chemical group 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- DFUYAWQUODQGFF-UHFFFAOYSA-N 1-ethoxy-1,1,2,2,3,3,4,4,4-nonafluorobutane Chemical compound CCOC(F)(F)C(F)(F)C(F)(F)C(F)(F)F DFUYAWQUODQGFF-UHFFFAOYSA-N 0.000 claims 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims 1
- 229960004150 aciclovir Drugs 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 239000006184 cosolvent Substances 0.000 claims 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 1
- 239000004205 dimethyl polysiloxane Substances 0.000 claims 1
- 239000003925 fat Substances 0.000 claims 1
- 229960002963 ganciclovir Drugs 0.000 claims 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 229960001295 tocopherol Drugs 0.000 claims 1
- 229930003799 tocopherol Natural products 0.000 claims 1
- 235000010384 tocopherol Nutrition 0.000 claims 1
- 239000011732 tocopherol Substances 0.000 claims 1
- 239000002544 virustatic Substances 0.000 claims 1
- 230000001790 virustatic effect Effects 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 238000000034 method Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 4
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 238000005138 cryopreservation Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- DIOQZVSQGTUSAI-NJFSPNSNSA-N decane Chemical compound CCCCCCCCC[14CH3] DIOQZVSQGTUSAI-NJFSPNSNSA-N 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000004508 fractional distillation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- DIOQZVSQGTUSAI-UHFFFAOYSA-N n-butylhexane Natural products CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- BPHQIXJDBIHMLT-UHFFFAOYSA-N perfluorodecane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F BPHQIXJDBIHMLT-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- 150000004756 silanes Chemical class 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005055811A DE102005055811A1 (de) | 2005-11-23 | 2005-11-23 | Verwendung einer Zusammensetzung zur Konservierung von Organen und Gliedmaßen |
| PCT/EP2006/011247 WO2007059968A2 (de) | 2005-11-23 | 2006-11-23 | Verwendung einer zusammensetzung zur konservierung von organen und gliedmassen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ568206A true NZ568206A (en) | 2011-05-27 |
Family
ID=37965062
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ568206A NZ568206A (en) | 2005-11-23 | 2006-11-23 | Use of a composition for preserving organs and limbs |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8029977B2 (https=) |
| EP (1) | EP1956895B1 (https=) |
| JP (1) | JP5344924B2 (https=) |
| KR (1) | KR101058744B1 (https=) |
| CN (1) | CN101312647B (https=) |
| AT (1) | ATE509522T1 (https=) |
| AU (1) | AU2006316738B2 (https=) |
| BR (1) | BRPI0618805A2 (https=) |
| CA (1) | CA2628085C (https=) |
| DE (1) | DE102005055811A1 (https=) |
| DK (1) | DK1956895T3 (https=) |
| ES (1) | ES2365415T3 (https=) |
| IL (1) | IL191133A0 (https=) |
| NZ (1) | NZ568206A (https=) |
| WO (1) | WO2007059968A2 (https=) |
| ZA (1) | ZA200803599B (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100785656B1 (ko) * | 2007-05-14 | 2007-12-17 | 재단법인서울대학교산학협력재단 | 소염제로 사용되는 소디움글리코콜레이트 또는 그 유도체 |
| EP2110126B9 (de) * | 2008-04-18 | 2012-09-19 | Novaliq GmbH | Inhalative und instillative Verwendung von semifluorierten Alkanen als Wirkstoffträger im intrapulmonalen Bereich |
| EP2335692A1 (en) * | 2009-12-04 | 2011-06-22 | AL.CHI.MI.A. S.r.l. | Silicone liquid and fluorinated liquid for sequential use in the treatment of retinal tears and/or detachments |
| WO2011113855A2 (en) | 2010-03-17 | 2011-09-22 | Novaliq Gmbh | Pharmaceutical composition for treatment of increased intraocular pressure |
| EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
| EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
| CN107397718A (zh) | 2011-05-25 | 2017-11-28 | 诺瓦利克有限责任公司 | 基于半氟化烷烃类的外用药物组合物 |
| KR101989648B1 (ko) | 2012-01-23 | 2019-06-14 | 노바리크 게엠베하 | 부분불소화 알칸에 기초한 안정화된 단백질 조성물 |
| DK3181119T3 (da) | 2012-09-12 | 2019-09-16 | Novaliq Gmbh | Semifluorerede alkansammensætninger til anvendelse ved behandling af keratoconjunctivitis sicca |
| CN113679697A (zh) | 2012-09-12 | 2021-11-23 | 诺瓦利克有限责任公司 | 包含半氟化烷烃的混合物的组合物 |
| KR101284530B1 (ko) * | 2012-11-13 | 2013-07-16 | 공주대학교 산학협력단 | 생물학적 영구표본 제작용 치환제 및 이의 용도 |
| BR112016001522B1 (pt) | 2013-07-23 | 2019-10-01 | Novaliq Gmbh | Composições de anticorpo estabilizado |
| CN108348777B (zh) | 2015-09-30 | 2020-04-28 | 诺瓦利克有限责任公司 | 半氟化化合物和其组合物 |
| MX2018003781A (es) * | 2015-09-30 | 2018-09-12 | Novaliq Gmbh | Compuestos semifluorados para administracion oftalmica. |
| CN105248412A (zh) * | 2015-10-30 | 2016-01-20 | 暨南大学 | 一种乳化氟碳液在制备肺器官保存液中的应用 |
| USRE50060E1 (en) | 2016-06-23 | 2024-07-30 | Novaliq Gmbh | Topical administration method |
| ES2969758T3 (es) | 2016-09-22 | 2024-05-22 | Novaliq Gmbh | Composiciones farmacéuticas para usar en la terapia de la blefaritis |
| US10813976B2 (en) | 2016-09-23 | 2020-10-27 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
| PT3399962T (pt) | 2016-12-23 | 2020-09-03 | Novaliq Gmbh | Composição oftálmica para o tratamento da doença do olho seco |
| CA3058097C (en) | 2017-04-21 | 2024-01-02 | Novaliq Gmbh | Iodine compositions |
| US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
| KR20200059272A (ko) | 2017-09-27 | 2020-05-28 | 노바리크 게엠베하 | 안구 질환의 치료에서의 사용을 위한 라타노프로스트를 포함하는 안과적 조성물 |
| CN111182893A (zh) | 2017-10-04 | 2020-05-19 | 诺瓦利克有限责任公司 | 包含f6h8的眼用组合物 |
| EP3758676A1 (en) | 2018-03-02 | 2021-01-06 | Novaliq GmbH | Pharmaceutical compositions comprising nebivolol |
| KR102882058B1 (ko) | 2018-03-28 | 2025-11-07 | 노바리크 게엠베하 | 티몰롤을 포함하는 약제학적 조성물 |
| JP2021522219A (ja) | 2018-04-27 | 2021-08-30 | ノバリック ゲーエムベーハー | 緑内障の治療のためのタフルプロストを含む眼科用組成物 |
| WO2020064556A1 (en) | 2018-09-27 | 2020-04-02 | Novaliq Gmbh | Topical sunscreen formulation |
| WO2020064549A1 (en) | 2018-09-27 | 2020-04-02 | Novaliq Gmbh | Lipid barrier repair |
| SG11202102820VA (en) | 2018-10-12 | 2021-04-29 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
| CN113710228A (zh) | 2019-02-13 | 2021-11-26 | 诺瓦利克有限责任公司 | 用于治疗眼部新生血管形成的组合物和方法 |
| US12419933B2 (en) | 2019-09-06 | 2025-09-23 | Novaliq Gmbh | Ophthalmic composition for the treatment of uveitis |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0440925A1 (en) | 1989-12-13 | 1991-08-14 | The Green Cross Corporation | Internal organ-preserving liquid and method for preserving internal organs |
| FR2679150A1 (fr) * | 1991-07-17 | 1993-01-22 | Atta | Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations. |
| DE4205341A1 (de) | 1992-02-21 | 1993-08-26 | Pharmpur Gmbh | Verfahren zur reinigung von perfluorcarbonen und verwendung der gereinigten perfluorcarbone |
| FR2716678B1 (fr) * | 1994-02-25 | 1996-05-15 | Opsia | Nouveaux composés organiques fluorés, applications en particulier ophtalmologiques et procédé de fabrication. |
| DE19536504C2 (de) * | 1995-09-29 | 1999-09-23 | H Meinert | Verwendung fluorierter Alkane |
| JPH09157251A (ja) | 1995-10-06 | 1997-06-17 | Kanegafuchi Chem Ind Co Ltd | Ｎ−（Ｄ−α−メチル−β−メルカプトプロピオニル）−Ｌ−プロリン及び該中間体の製造方法 |
| US5952168A (en) * | 1996-11-07 | 1999-09-14 | 21St Century Medicine, Inc. | Method for vitrification of biological materials using alkoxylated compounds |
| US6475716B1 (en) * | 2001-03-06 | 2002-11-05 | Biobank Co., Ltd. | Method for preserving mammalian organs |
-
2005
- 2005-11-23 DE DE102005055811A patent/DE102005055811A1/de not_active Withdrawn
-
2006
- 2006-11-23 CA CA2628085A patent/CA2628085C/en not_active Expired - Fee Related
- 2006-11-23 JP JP2008541642A patent/JP5344924B2/ja not_active Expired - Fee Related
- 2006-11-23 US US12/094,951 patent/US8029977B2/en not_active Expired - Fee Related
- 2006-11-23 KR KR1020087013057A patent/KR101058744B1/ko not_active Expired - Fee Related
- 2006-11-23 EP EP06806724A patent/EP1956895B1/de not_active Not-in-force
- 2006-11-23 AU AU2006316738A patent/AU2006316738B2/en not_active Ceased
- 2006-11-23 DK DK06806724.8T patent/DK1956895T3/da active
- 2006-11-23 WO PCT/EP2006/011247 patent/WO2007059968A2/de not_active Ceased
- 2006-11-23 BR BRPI0618805-2A patent/BRPI0618805A2/pt not_active Application Discontinuation
- 2006-11-23 NZ NZ568206A patent/NZ568206A/en not_active IP Right Cessation
- 2006-11-23 ES ES06806724T patent/ES2365415T3/es active Active
- 2006-11-23 AT AT06806724T patent/ATE509522T1/de active
- 2006-11-23 CN CN2006800437943A patent/CN101312647B/zh not_active Expired - Fee Related
-
2008
- 2008-04-23 ZA ZA200803599A patent/ZA200803599B/xx unknown
- 2008-04-29 IL IL191133A patent/IL191133A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007059968A2 (de) | 2007-05-31 |
| CA2628085C (en) | 2013-06-04 |
| DK1956895T3 (da) | 2011-07-25 |
| EP1956895B1 (de) | 2011-05-18 |
| ES2365415T3 (es) | 2011-10-04 |
| EP1956895A2 (de) | 2008-08-20 |
| ZA200803599B (en) | 2009-02-25 |
| AU2006316738A1 (en) | 2007-05-31 |
| US20090226875A1 (en) | 2009-09-10 |
| US8029977B2 (en) | 2011-10-04 |
| DE102005055811A1 (de) | 2007-05-31 |
| HK1126622A1 (en) | 2009-09-11 |
| CA2628085A1 (en) | 2007-05-31 |
| BRPI0618805A2 (pt) | 2011-09-13 |
| WO2007059968A3 (de) | 2008-07-10 |
| CN101312647B (zh) | 2012-06-27 |
| IL191133A0 (en) | 2008-12-29 |
| KR101058744B1 (ko) | 2011-08-24 |
| KR20080064998A (ko) | 2008-07-10 |
| AU2006316738B2 (en) | 2011-10-13 |
| CN101312647A (zh) | 2008-11-26 |
| JP5344924B2 (ja) | 2013-11-20 |
| ATE509522T1 (de) | 2011-06-15 |
| JP2009516717A (ja) | 2009-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2628085C (en) | Use of a composition for preserving organs and limbs | |
| CA1312011C (en) | Concentrated stable fluorochemical aqueous emulsions | |
| JP5562992B2 (ja) | 制御放出組成物 | |
| JPS6210201B2 (https=) | ||
| EP0187816A1 (en) | Prolonged storage of red blood cells. | |
| KR970701066A (ko) | 초음파 가스 현탁물의 저장 방법(Method of Storage of Ultrasonic Gas Suspensions) | |
| ES2217161T3 (es) | Composiciones liquidas ambientadoras o insecticidas y su uso. | |
| MX2008006402A (en) | Use of a composition for preserving organs and members | |
| HK1126622B (en) | Use of a composition for preserving organs and limbs | |
| ES2382684T3 (es) | Preparación adhesiva que contiene fentanilo | |
| US12268205B2 (en) | Medium and methods for the storage of red blood cells | |
| WO2002009516A2 (en) | Carrier solution for vitrifiable concentrations of cryoprotectants, and cryoprotectant mixtures | |
| Yoshikami et al. | [60] Technique for introducing retinol analogs into the isolated retina | |
| EP3276315A1 (en) | Temperature-regulating medium | |
| JP3669080B2 (ja) | 鮮度保持剤及びその製造法 | |
| JPH06183920A (ja) | イソチオシアン酸エステル蒸気発生剤及びそれを用いた殺菌処理方法 | |
| JPWO2007046318A1 (ja) | インドメタシンを含有する外用液剤 | |
| Naumann | Influence of PFAS on the Thermodynamic Membrane Properties and Growth of A. Borkumensis | |
| JPH0236111B2 (https=) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 23 NOV 2016 BY PAVIS EG Effective date: 20131112 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 NOV 2017 BY PAVIS GMBH Effective date: 20161110 |
|
| LAPS | Patent lapsed |